BridgeMD
The efficacy of oral vancomycin therapy in managing different phenotypes of paediatric inflammatory bowel diseases by correlating treatment response to commensal microbiota composition and function
EU CTIS ID: 2025-524543-12-00
What this study is testing
Comparing pre-post treatment clinical findings in correlation with changes in commensal microbiota composition and function
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 6-16 years old with established diagnosis of atypical UC (presenting right-sided colitis, backwash ileitis, or rectal sparing, and/or positive atypical pANCA or PR3-ANCA) with confirmed PSC in MRCP (PSC-UC) or without detectable PSC (aUC-non-PSC), and children with typical UC without PSC
- Has nor received OVT preciously, but patients and/or their guardians has given an informed consent to commence OVT for at least 3 months for treating PSC-UC or aUC-non-PSC
- Able to swallow capsules
- Do not have active infection (such as clostridium or other bacteria) if the clinical stool screening before starting OVT
- No new interventions (medications or new conventional therapies) for treating IBD was given within the past 4 weeks before starting OVT • May use contraceptives or other medications that are not antibiotics
- May use contraceptives or other medications that are not antibiotics
You likely can't join if
- PSC without UC; Crohn’s disease type of inflammatory bowel diseases.
- Under the age of 6 years old
- Is unable to swallow capsules
- Had a previous allergic reactions to vancomycin (such as vancomycin allergy) and/or other related antibiotics similar to vancomycin
- Presence of malignant disease or potential need for liver transplantation within the following 12 months
- Pregnancy
See the full eligibility criteria
- 6-16 years old with established diagnosis of atypical UC (presenting right-sided colitis, backwash ileitis, or rectal sparing, and/or positive atypical pANCA or PR3-ANCA) with confirmed PSC in MRCP (PSC-UC) or without detectable PSC (aUC-non-PSC), and children with typical UC without PSC
- Has nor received OVT preciously, but patients and/or their guardians has given an informed consent to commence OVT for at least 3 months for treating PSC-UC or aUC-non-PSC
- Able to swallow capsules
- Do not have active infection (such as clostridium or other bacteria) if the clinical stool screening before starting OVT
- No new interventions (medications or new conventional therapies) for treating IBD was given within the past 4 weeks before starting OVT • May use contraceptives or other medications that are not antibiotics
- May use contraceptives or other medications that are not antibiotics
- For healthy participant: no symptoms or suspicion of inflammatory bowel diseases but are scheduled for endoscopy for other reasons
- PSC without UC; Crohn’s disease type of inflammatory bowel diseases.
- Under the age of 6 years old
- Is unable to swallow capsules
- Had a previous allergic reactions to vancomycin (such as vancomycin allergy) and/or other related antibiotics similar to vancomycin
- Presence of malignant disease or potential need for liver transplantation within the following 12 months
- Pregnancy
- For healthy controls: presence of chronic illness requiring long-term medications, use of antibiotics within the past 6 months
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.